Neurotrophic factors for the treatment of Parkinson's disease

Cytokine and Growth Factor Reviews

Volumn 22, Issue 3, 2011, Pages 157-165

  Sullivan, Aideen M ^a   Toulouse, André ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Cerebral dopaminergic neurotrophic factor; Glial cell line derived neurotrophic factor; Growth differentiation factor 5; Mesencephalic astrocyte derived neurotrophic factor; Neurturin

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; ARTEMIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 1B; CERE 120; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR ANTIBODY; GROWTH DIFFERENTIATION FACTOR 5; LENTIVIRUS VECTOR; LEVODOPA; NEUROTROPHIC FACTOR; NEURTURIN; PARVOVIRUS VECTOR; PERSEPHIN; PLACEBO; RECOMBINANT GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; RECOMBINANT METHIONYL GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; RECOMBINANT NEURTURIN; UNCLASSIFIED DRUG;

ANOREXIA; CELL ENCAPSULATION; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG ADMINISTRATION ROUTE; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DYSKINESIA; EX VIVO GENE TRANSFER; HUMAN; INTRAPUTAMINAL INJECTION; L HERMITTE SIGN; MEDIAL FOREBRAIN BUNDLE; MESENCEPHALON; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NAUSEA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATIENT SELECTION; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADULT; ANIMALS; BRAIN; DOPAMINERGIC NEURONS; HUMANS; NERVE GROWTH FACTORS; PARKINSON DISEASE; SYNAPTIC TRANSMISSION;

EID: 80052337005     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2011.05.001     Document Type: Short Survey

References (140)

1. Toulouse A., Sullivan A.M. Progress in Parkinson's disease - where do we stand?. Prog Neurobiol 2008, 85:376-392.
2. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
3. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
4. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
5. Long-Smith C.M., Sullivan A.M., Nolan Y.M. The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol 2009, 89:277-287.
6. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
7. Aron L., Klein R. Repairing the parkinsonian brain with neurotrophic factors. Trends Neurosci 2011, 34:88-100.
8. Theofilopoulos S., Goggi J., Riaz S.S., Jauniaux E., Stern G.M., Bradford H.F. Parallel induction of the formation of dopamine and its metabolites with induction of tyrosine hydroxylase expression in foetal rat and human cerebral cortical cells by brain-derived neurotrophic factor and glial-cell derived neurotrophic factor. Brain Res Dev Brain Res 2001, 127:111-122.
9. Krieglstein K., Suter-Crazzolara C., Fischer W.H., Unsicker K. TGF-beta superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity. EMBO J 1995, 14:736-742.
10. Widmer H.R., Schaller B., Meyer M., Seiler R.W. Glial cell line-derived neurotrophic factor stimulates the morphological differentiation of cultured ventral mesencephalic calbindin- and calretinin-expressing neurons. Exp Neurol 2000, 164:71-81.
11. Eggert K., Schlegel J., Oertel W., Wurz C., Krieg J.C., Vedder H. Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro. Neurosci Lett 1999, 269:178-182.
12. Hou J.G., Lin L.F., Mytilineou C. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J Neurochem 1996, 66:74-82.
13. Ma D., Wang X., Han J. NIH 3T3 cells or engineered NIH 3T3 cells stably expressing GDNF can protect primary dopaminergic neurons. Neurol Res 2000, 22:538-544.
14. Clarkson E.D., Zawada W.M., Freed C.R. GDNF reduces apoptosis in dopaminergic neurons in vitro. Neuroreport 1995, 7:145-149.
15. Sawada H., Ibi M., Kihara T., Urushitani M., Nakanishi M., Akaike A., et al. Neuroprotective mechanism of glial cell line-derived neurotrophic factor in mesencephalic neurons. J Neurochem 2000, 74:1175-1184.
16. Clarkson E.D., Zawada W.M., Freed C.R. GDNF improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro. Cell Tissue Res 1997, 289:207-210.
17. Xing B., Xin T., Zhao L., Hunter R.L., Chen Y., Bing G. Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity. J Neuroimmunol 2010, 225:43-51.
18. Burke R.E., Antonelli M., Sulzer D. Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture. J Neurochem 1998, 71:517-525.
19. Borgal L., Hong M., Sadi D., Mendez I. Differential effects of glial cell line-derived neurotrophic factor on A9 and A10 dopamine neuron survival in vitro. Neuroscience 2007, 147:712-719.
20. Martin D., Miller G., Cullen T., Fischer N., Dix D., Russell D. Intranigral or intrastriatal injections of GDNF: effects on monoamine levels and behavior in rats. Eur J Pharmacol 1996, 317:247-256.
21. Ramaswamy S., Soderstrom K.E., Kordower J.H. Trophic factors therapy in Parkinson's disease. Prog Brain Res 2009, 175:201-216.
22. Beck K.D., Valverde J., Alexi T., Poulsen K., Moffat B., Vandlen R.A., et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995, 373:339-341.
23. Bowenkamp K.E., Hoffman A.F., Gerhardt G.A., Henry M.A., Biddle P.T., Hoffer B.J., et al. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J Comp Neurol 1995, 355:479-489.
24. Hoffer B.J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994, 182:107-111.
25. Opacka-Juffry J., Ashworth S., Hume S.P., Martin D., Brooks D.J., Blunt S.B. GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET. Neuroreport 1995, 7:348-352.
26. Bowenkamp K.E., Lapchak P.A., Hoffer B.J., Miller P.J., Bickford P.C. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats. Exp Neurol 1997, 145:104-117.
27. Fox C.M., Gash D.M., Smoot M.K., Cass W.A. Neuroprotective effects of GDNF against 6-OHDA in young and aged rats. Brain Res 2001, 896:56-63.
28. Kearns C.M., Gash D.M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 1995, 672:104-111.
29. Sauer H., Rosenblad C., Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci U S A 1995, 92:8935-8939.
30. Shults C.W., Kimber T., Martin D. Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine. Neuroreport 1996, 7:627-631.
31. Winkler C., Sauer H., Lee C.S., Bjorklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 1996, 16:7206-7215.
32. Sullivan A.M., Opacka-Juffry J., Blunt S.B. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. Eur J Neurosci 1998, 10:57-63.
33. Rosenblad C., Martinez-Serrano A., Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 1998, 82:129-137.
34. Kirik D., Rosenblad C., Bjorklund A., Mandel R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000, 20:4686-4700.
35. Kirik D., Winkler C., Bjorklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J Neurosci 2001, 21:2889-2896.
36. Aoi M., Date I., Tomita S., Ohmoto T. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages. Neurosci Res 2000, 36:319-325.
37. Rosenblad C., Kirik D., Bjorklund A. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp Neurol 2000, 161:503-516.
38. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373:335-339.
39. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380:252-255.
40. Miyoshi Y., Zhang Z., Ovadia A., Lapchak P.A., Collins F., Hilt D., et al. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann Neurol 1997, 42:208-214.
41. Iravani M.M., Costa S., Jackson M.J., Tel B.C., Cannizzaro C., Pearce R.K., et al. GDNF reverses priming for dyskinesia in MPTP-treated, l-DOPA-primed common marmosets. Eur J Neurosci 2001, 13:597-608.
42. Zhang Z., Miyoshi Y., Lapchak P.A., Collins F., Hilt D., Lebel C., et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 1997, 282:1396-1401.
43. Gerhardt G.A., Cass W.A., Huettl P., Brock S., Zhang Z., Gash D.M. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res 1999, 817:163-171.
44. Grondin R., Zhang Z., Yi A., Cass W.A., Maswood N., Andersen A.H., et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 2002, 125:2191-2201.
45. Maswood N., Grondin R., Zhang Z., Stanford J.A., Surgener S.P., Gash D.M., et al. Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys. Neurobiol Aging 2002, 23:881-889.
46. Choi-Lundberg D.L., Lin Q., Chang Y.N., Chiang Y.L., Hay C.M., Mohajeri H., et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997, 275:838-841.
47. Mandel R.J., Spratt S.K., Snyder R.O., Leff S.E. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci U S A 1997, 94:14083-14088.
48. Bilang-Bleuel A., Revah F., Colin P., Locquet I., Robert J.J., Mallet J., et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 1997, 94:8818-8823.
49. Choi-Lundberg D.L., Lin Q., Schallert T., Crippens D., Davidson B.L., Chang Y.N., et al. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp Neurol 1998, 154:261-275.
50. Kozlowski D.A., Connor B., Tillerson J.L., Schallert T., Bohn M.C. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Exp Neurol 2000, 166:1-15.
51. Kojima H., Abiru Y., Sakajiri K., Watabe K., Ohishi N., Takamori M., et al. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain. Biochem Biophys Res Commun 1997, 238:569-573.
52. Connor B., Kozlowski D.A., Schallert T., Tillerson J.L., Davidson B.L., Bohn M.C. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther 1999, 6:1936-1951.
53. Mandel R.J., Snyder R.O., Leff S.E. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Exp Neurol 1999, 160:205-214.
54. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290:767-773.
55. Emborg M.E., Moirano J., Raschke J., Bondarenko V., Zufferey R., Peng S., et al. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis 2009, 36:303-311.
56. Palfi S., Leventhal L., Chu Y., Ma S.Y., Emborg M., Bakay R., et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci 2002, 22:4942-4954.
57. Brundin P., Barker R.A., Parmar M. Neural grafting in Parkinson's disease: problems and possibilities. Prog Brain Res 2010, 184:265-294.
58. Rosenblad C., Martinez-Serrano A., Bjorklund A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 1996, 75:979-985.
59. Apostolides C., Sanford E., Hong M., Mendez I. Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells. Neuroscience 1998, 83:363-372.
60. Granholm A.C., Mott J.L., Bowenkamp K., Eken S., Henry S., Hoffer B.J., et al. Glial cell line-derived neurotrophic factor improves survival of ventral mesencephalic grafts to the 6-hydroxydopamine lesioned striatum. Exp Brain Res 1997, 116:29-38.
61. Sullivan A.M., Pohl J., Blunt S.B. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. Eur J Neurosci 1998, 10:3681-3688.
62. Yurek D.M. Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Exp Neurol 1998, 153:195-202.
63. Sinclair S.R., Svendsen C.N., Torres E.M., Martin D., Fawcett J.W., Dunnett S.B. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. Neuroreport 1996, 7:2547-2552.
64. Tang F.I., Tien L.T., Zhou F.C., Hoffer B.J., Wang Y. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats. Exp Brain Res 1998, 119:287-296.
65. Wang Y., Tien L.T., Lapchak P.A., Hoffer B.J. GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats. Cell Tissue Res 1996, 286:225-233.
66. Mehta V., Hong M., Spears J., Mendez I. Enhancement of graft survival and sensorimotor behavioral recovery in rats undergoing transplantation with dopaminergic cells exposed to glial cell line-derived neurotrophic factor. J Neurosurg 1998, 88:1088-1095.
67. Mendez I., Dagher A., Hong M., Hebb A., Gaudet P., Law A., et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J Neurosurg 2000, 92:863-869.
68. Bauer M., Meyer M., Grimm L., Meitinger T., Zimmer J., Gasser T., et al. Nonviral glial cell-derived neurotrophic factor gene transfer enhances survival of cultured dopaminergic neurons and improves their function after transplantation in a rat model of Parkinson's disease. Hum Gene Ther 2000, 11:1529-1541.
69. Ostenfeld T., Tai Y.T., Martin P., Deglon N., Aebischer P., Svendsen C.N. Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. J Neurosci Res 2002, 69:955-965.
70. Behrstock S., Ebert A., McHugh J., Vosberg S., Moore J, Schneider B., et al. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. Gene Ther 2006, 13:379-388.
71. Date I., Shingo T., Yoshida H., Fujiwara K., Kobayashi K., Takeuchi A., et al. Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats. Cell Transplant 2001, 10:397-401.
72. Shingo T., Date I., Yoshida H., Ohmoto T. Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF-producing cells in a rat model of Parkinson's disease. J Neurosci Res 2002, 69:946-954.
73. Yasuhara T., Shingo T., Muraoka K., Kobayashi K, Takeuchi A., Yano A., et al. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. J Neurosurg 2005, 102:80-89.
74. Sajadi A., Bensadoun J.C., Schneider B.L., Lo Bianco C., Aebischer P. Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease. Neurobiol Dis 2006, 22:119-129.
75. Kishima H., Poyot T., Bloch J., Dauguet J., Conde F., Dolle F., et al. Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. Neurobiol Dis 2004, 16:428-439.
76. Sautter J., Tseng J.L., Braguglia D., Aebischer P., Spenger C., Seiler R.W., et al. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp Neurol 1998, 149:230-236.
77. Lindvall O., Wahlberg L.U. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?. Exp Neurol 2008, 209:82-88.
78. Kotzbauer P.T., Lampe P.A., Heuckeroth R.O., Golden J.P., Creedon D.J., Johnson E.M., et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 1996, 384:467-470.
79. Akerud P., Alberch J., Eketjall S., Wagner J., Arenas E. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons. J Neurochem 1999, 73:70-78.
80. Horger B.A., Nishimura M.C., Armanini M.P., Wang L.C., Poulsen K.T., Rosenblad C., et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 1998, 18:4929-4937.
81. Oiwa Y., Yoshimura R., Nakai K., Itakura T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res 2002, 947:271-283.
82. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H.S., Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 1999, 11:1554-1566.
83. Tseng J.L., Bruhn S.L., Zurn A.D., Aebischer P. Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy. Neuroreport 1998, 9:1817-1822.
84. Hoane M.R., Gulwadi A.G., Morrison S., Hovanesian G., Lindner M.D., Tao W. Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor. Exp Neurol 1999, 160:235-243.
85. Cass W.A., Peters L.E. Neurturin effects on nigrostriatal dopamine release and content: comparison with GDNF. Neurochem Res 2010, 35:727-734.
86. Grondin R., Zhang Z., Ai Y., Ding F., Walton A.A., Surgener S.P., et al. Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeys. Cell Transplant 2008, 17:373-381.
87. Li H., He Z., Su T., Ma Y., Lu S., Dai C., et al. Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a rhesus monkey model of Parkinson's disease. Neurol Res 2003, 25:263-267.
88. Rosenblad C., Kirik D., Bjorklund A. Neurturin enhances the survival of intrastriatal fetal dopaminergic transplants. Neuroreport 1999, 10:1783-1787.
89. Fjord-Larsen L., Johansen J.L., Kusk P., Tornoe J., Gronborg M., Rosenblad C., et al. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp Neurol 2005, 195:49-60.
90. Kordower J.H., Herzog C.D., Dass B., Bakay R.A., Stansell J, 3rd, Gasmi M., et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 2006, 60:706-715.
91. Gasmi M., Brandon E.P., Herzog C.D., Wilson A., Bishop K.M., Hofer E.K., et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis 2007, 27:67-76.
92. Gasmi M., Herzog C.D., Brandon E.P., Cunningham J.J., Ramirez G.A., Ketchum E.T., et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther 2007, 15:62-68.
93. Herzog C.D., Dass B., Holden J.E., Stansell J, 3rd, Gasmi M., Tuszynski M.H., et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 2007, 22:1124-1132.
94. Herzog C.D., Brown L., Gammon D., Kruegel B., Lin R., Wilson A., et al. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery 2009, 64:602-612. [discussion 612-3].
95. Bartus R.T., Herzog C.D., Bishop K., Ostrove J.M., Tuszynski M., Kordower J.H., et al. Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point. Parkinsonism Relat Disord 2007, 13(Suppl. 3):S469-S477.
96. Milbrandt J., de Sauvage F.J., Fahrner T.J., Baloh R.H., Leitner M.L., Tansey M.G., et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 1998, 20:245-253.
97. Akerud P., Holm P.C., Castelo-Branco G., Sousa K., Rodriguez F.J., Arenas E. Persephin-overexpressing neural stem cells regulate the function of nigral dopaminergic neurons and prevent their degeneration in a model of Parkinson's disease. Mol Cell Neurosci 2002, 21:205-222.
98. Baloh R.H., Tansey M.G., Lampe P.A., Fahrner T.J., Enomoto H., Simburger K.S., et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 1998, 21:1291-1302.
99. Cass W.A., Peters L.E., Harned M.E., Seroogy K.B. Protection by GDNF and other trophic factors against the dopamine-depleting effects of neurotoxic doses of methamphetamine. Ann N Y Acad Sci 2006, 1074:272-281.
100. Gardell L.R., Wang R., Ehrenfels C., Ossipov M.H., Rossomando A.J., Miller S., et al. Multiple actions of systemic artemin in experimental neuropathy. Nat Med 2003, 9:1383-1389.
101. Hall A.K., Miller R.H. Emerging roles for bone morphogenetic proteins in central nervous system glial biology. J Neurosci Res 2004, 76:1-8.
102. Krieglstein K., Suter-Crazzolara C., Hotten G., Pohl J., Unsicker K. Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor-beta superfamily, on midbrain dopaminergic neurons. J Neurosci Res 1995, 42:724-732.
103. O'Keeffe G.W., Hanke M., Pohl J., Sullivan A.M. Expression of growth differentiation factor-5 in the developing and adult rat brain. Brain Res Dev Brain Res 2004, 151:199-202.
104. Storm E.E., Huynh T.V., Copeland N.G., Jenkins N.A., Kingsley D.M., Lee S.J. Limb alterations in brachypodism mice due to mutations in a new member of the TGF beta-superfamily. Nature 1994, 368:639-643.
105. Lingor P., Unsicker K., Krieglstein K. Midbrain dopaminergic neurons are protected from radical induced damage by GDF-5 application. Short communication. J Neural Transm 1999, 106:139-144.
106. O'Keeffe G.W., Dockery P., Sullivan A.M. Effects of growth/differentiation factor 5 on the survival and morphology of embryonic rat midbrain dopaminergic neurones in vitro. J Neurocytol 2004, 33:479-488.
107. Clayton K.B., Sullivan A.M. Differential effects of GDF5 on the medial and lateral rat ventral mesencephalon. Neurosci Lett 2007, 427:132-137.
108. Wood T.K., McDermott K.W., Sullivan A.M. Differential effects of growth/differentiation factor 5 and glial cell line-derived neurotrophic factor on dopaminergic neurons and astroglia in cultures of embryonic rat midbrain. J Neurosci Res 2005, 80:759-766.
109. Sullivan A.M., Opacka-Juffry J., Hotten G., Pohl J., Blunt S.B. Growth/differentiation factor 5 protects nigrostriatal dopaminergic neurones in a rat model of Parkinson's disease. Neurosci Lett 1997, 233:73-76.
110. Sullivan A.M., Opacka-Juffry J., Pohl J., Blunt S.B. Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration. Brain Res 1999, 818:176-179.
111. Hurley F.M., Costello D.J., Sullivan A.M. Neuroprotective effects of delayed administration of growth/differentiation factor-5 in the partial lesion model of Parkinson's disease. Exp Neurol 2004, 185:281-289.
112. O'Sullivan D.B., Harrison P.T., Sullivan A.M. Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo. J Neural Transm 2010, 117:559-572.
113. Lindholm P., Saarma M. Novel CDNF/MANF family of neurotrophic factors. Dev Neurobiol 2010, 70:360-371.
114. Lindholm P., Voutilainen M.H., Lauren J., Peranen J., Leppanen V.M., Andressoo J.O., et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007, 448:73-77.
115. Petrova P., Raibekas A., Pevsner J., Vigo N., Anafi M., Moore M.K., et al. MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci 2003, 20:173-188.
116. Choi J.M., Hong J.H., Chae M.J., Hung N.P., Kang H.S., Ma H.I., et al. Analysis of mutations and the association between polymorphisms in the cerebral dopamine neurotrophic factor (CDNF) gene and Parkinson disease. Neurosci Lett 2011, 493:97-101.
117. Lindholm P., Peranen J., Andressoo J.O., Kalkkinen N., Kokaia Z., Lindvall O., et al. MANF is widely expressed in mammalian tissues and differently regulated after ischemic and epileptic insults in rodent brain. Mol Cell Neurosci 2008, 39:356-371.
118. Palgi M., Lindstrom R., Peranen J., Piepponen T.P., Saarma M., Heino T.I. Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic neurons. Proc Natl Acad Sci U S A 2009, 106:2429-2434.
119. Voutilainen M.H., Back S., Porsti E., Toppinen L., Lindgren L., Lindholm P., et al. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J Neurosci 2009, 29:9651-9659.
120. Hellman M., Arumae U., Yu L.Y., Lindholm P., Peranen J., Saarma M., et al. Mesencephalic astrocyte-derived neurotrophic factor (MANF) has a unique mechanism to rescue apoptotic neurons. J Biol Chem 2011, 286:2675-2680.
121. Voutilainen M.H., Back S., Peranen J., Lindholm P., Raasmaja A., Mannisto P.T., et al. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Exp Neurol 2011, 228:99-108.
122. Leitner M.L., Molliver D.C., Osborne P.A., Vejsada R., Golden J.P., Lampe P.A., et al. Analysis of the retrograde transport of glial cell line-derived neurotrophic factor (GDNF), neurturin, and persephin suggests that in vivo signaling for the GDNF family is GFRalpha coreceptor-specific. J Neurosci 1999, 19:9322-9331.
123. Tomac A., Widenfalk J., Lin L.F., Kohno T., Ebendal T., Hoffer B.J., et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc Natl Acad Sci U S A 1995, 92:8274-8278.
124. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws E.R., et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60:69-73.
125. Kordower J.H., Palfi S., Chen E.Y., Ma S.Y., Sendera T., Cochran E.J., et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999, 46:419-424.
126. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003, 9:589-595.
127. Love S., Plaha P., Patel N.K., Hotton G.R., Brooks D.J., Gill S.S. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 2005, 11:703-704.
128. Patel N.K., Bunnage M., Plaha P., Svendsen C.N., Heywood P., Gill S.S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 2005, 57:298-302.
129. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2005, 102:216-222.
130. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006, 59:459-466.
131. Tatarewicz S.M., Wei X., Gupta S., Masterman D., Swanson S.J., Moxness M.S. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol 2007, 27:620-627.
132. Hovland D.N., Boyd R.B., Butt M.T., Engelhardt J.A., Moxness M.S., Ma M.H., et al. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol Pathol 2007, 35:676-692.
133. Barker R.A. Continuing trials of GDNF in Parkinson's disease. Lancet Neurol 2006, 5:285-286.
134. Lang A.E., Langston J.W., Stoessl A.J., Brodsky M., Brooks D.J., Dhawan V., et al. GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol 2006, 5:200-202.
135. Penn R.D., Dalvi A., Slevin J., et al. GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol 2006, 5:202-203.
136. Richardson R.M., Kells A.P., Rosenbluth K.H., et al. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther 2011, 19:1048-1057.
137. Evans J.R., Barker R.A. Neurotrophic factors as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets 2008, 12:437-447.
138. Marks W.J., Ostrem J.L., Verhagen L., et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008, 7:400-408.
139. Marks W.J., Bartus R.T., Siffert J., et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010, 9:1164-1172.
140. Bartus R.T., Herzog C.D., Chu Y., et al. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord 2011, 26:27-36.